期刊
CANCER
卷 126, 期 17, 页码 4023-4031出版社
WILEY
DOI: 10.1002/cncr.33042
关键词
anticancer treatment; cancer; case fatality rate; coronavirus disease 2019 (COVID-19); systemic therapy
类别
资金
- Health Commission of Hubei Province Scientific Research Project [WJ2019H002]
- Fundamental Research Funds for the Central Universities [2042018kf1037, 2042019kf0329]
- Medical Science Advancement Program (Basic Medical Sciences) of Wuhan University [TFJC2018005]
- Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund [znpy2017049, znpy2018070]
- National Medical Research Council Clinician-scientist award [NMRC/CSA/0027/2018]
- National Science and Technology Major Projects for Major New Drugs Innovation and Development [2019ZX09301010]
- Pudong New Area Science and Technology Development Foundation [PKX2019-S08]
Background Patients with cancer have a higher risk of coronavirus disease 2019 (COVID-19) than noncancer patients. The authors conducted a multicenter retrospective study to investigate the clinical manifestations and outcomes of patients with cancer who are diagnosed with COVID-19. Methods The authors reviewed the medical records of hospitalized patients who were treated at 5 hospitals in Wuhan City, China, between January 5 and March 18, 2020. Clinical parameters relating to cancer history (type and treatment) and COVID-19 were collected. The primary outcome was overall survival (OS). Secondary analyses were the association between clinical factors and severe COVID-19 and OS. Results A total of 107 patients with cancer were diagnosed with COVID-19, with a median age of 66 years (range, 37-98 years). Lung (21 patients; 19.6%), gastrointestinal (20 patients; 18.7%), and genitourinary (20 patients; 18.7%) cancers were the most common cancer diagnoses. A total of 37 patients (34.6%) were receiving active anticancer treatment when diagnosed with COVID-19, whereas 70 patients (65.4%) were on follow-up. Overall, 52.3% of patients (56 patients) developed severe COVID-19; this rate was found to be higher among patients receiving anticancer treatment than those on follow-up (64.9% vs 45.7%), which corresponded to an inferior OS in the former subgroup of patients (hazard ratio, 3.365; 95% CI, 1.455-7.782 [P = .005]). The detrimental effect of anticancer treatment on OS was found to be independent of exposure to systemic therapy (case fatality rate of 33.3% [systemic therapy] vs 43.8% [nonsystemic therapy]). Conclusions The results of the current study demonstrated that >50.0% of infected patients with cancer are susceptible to severe COVID-19. This risk is aggravated by simultaneous anticancer treatment and portends for a worse survival, despite treatment for COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据